The TANDEM phase 2b trial (NCT03517540) reported that in patients with biopsy-proven NASH with fibrosis, combined treatment with CVC plus tropifexor was safe, decreased body weight and ALT. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.